



### Company Overview

iBio, Inc. (NYSE MKT: IBIO), a leader in the plant-made pharmaceutical field, develops and offers pharmaceutical product applications using its iBio Technology platform.

The iBio Technology platform is a proprietary, transformative technology for the production of biologics including monoclonal antibodies, other therapeutic proteins and vaccines.

### iBio Supporting AzarGen Biotechnologies' Development of a Rituximab Biosimilar

Mar 26 2020, 4:20 PM EDT

### iBio Announces Advancement of COVID-19 Vaccine Program

Mar 26 2020, 7:30 AM EDT

### iBio Joins the Alliance for Biosecurity

Mar 20 2020, 7:30 AM EDT

### Stock Overview

Symbol	IBIO
Exchange	NYSE American
Market Cap	117.6m
Last Price	\$1.15
52-Week	\$0.05 - \$3.40

03/27/2020 04:10 PM EDT

### Investor Relations

Stephen Kilmer  
T: 646-274-3580  
[skilmer@ibioinc.com](mailto:skilmer@ibioinc.com)

### Management Team

#### Thomas F. Isett

Co-Chairman of the Board & Chief Executive Officer

#### Robert L. Erwin

President

#### James P. Mullaney

Chief Financial Officer

### iBio Inc.

600 Madison Avenue  
Suite 1601  
New York, NY 10022

### Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.